Recordati

REC

IT0003828271

Pharmaceuticals

Market Closed - Borsa Italiana Other stock markets 12:45:00 2026-03-13 pm EDT			5-day change	1st Jan Change
45.48 ^EUR	-2.28%		-2.94%	-6.30%

Mar. 13	Diary - Europe's STOXX 600 Corporate Earnings Week Ahead	RE
Mar. 13	DIARY - Italy to April 30	RE

Recordati and Moderna Sign Global Agreement on mRNA Therapy for Rare Disease

Published on 01/30/2026 at 01:32 am EST - Modified on 01/30/2026 at 03:48 am EST

Alliance News - Translated by Marketscreener - See original

RECORDATI

-2.28%

MODERNA, INC.

-1.55%

Recordati and Moderna Sign Global Agreement on mRNA Therapy for Rare Disease

(Alliance News) - Recordati Spa has announced the signing of a collaboration and licensing agreement with Moderna for the development and global commercialization of mRNA-3927, an experimental drug aimed at treating propionic acidemia, a rare hereditary metabolic disorder.

Under the terms of the agreement, Recordati will make an upfront payment of USD50 million to Moderna, with up to an additional USD110 million tied to short-term development and regulatory milestones. Moderna will also be eligible to receive commercial and sales milestones, as well as tiered royalties on annual net sales. Recordati does not anticipate any significant impact on its EBITDA prior to a potential launch.

According to the agreement, Moderna will continue to lead the clinical development of the product in collaboration with Recordati, while Recordati will take the lead on global commercialization activities should the therapy be approved.

By Maurizio Carta, Alliance News reporter

Comments and questions to redazione@alliancenews.com

Stocks mentioned in the article

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	RECORDATI	45.48EUR	-2.28%	-2.94%	10.97B
	MODERNA, INC.	52.56USD	-1.55%	+0.08%	21.09B

Latest news about Recordati

Mar. 13	Diary - Europe's STOXX 600 Corporate Earnings Week Ahead	RE
Mar. 13	DIARY - Italy to April 30	RE
Mar. 10	Recordati acquires 114,393 treasury shares for over EUR5 million	AN
Mar. 06	DIARY - Italy to April 30	RE
Mar. 04	European Markets Expected to Rebound, Spotlight on Iran	AN
Mar. 03	Recordati Acquires 53,599 Treasury Shares for Nearly 𔚻3 Million	AN
Mar. 03	Sell-off Hits European Markets, Mib Drops to 44,400 Points	AN
Mar. 03	BNP Paribas Begins Recordati Coverage at Outperform	MT
Mar. 03	DIARY - Italy to April 30	RE
Mar. 03	Italy - Factors to watch on March 3	RE
Feb. 27	DIARY - Italy to April 30	RE
Feb. 25	DIARY - Italy to April 30	RE
Feb. 24	Recordati Acquires 54,591 Treasury Shares for Nearly EUR3 Million	AN
Feb. 24	Futures Flat, Focus Shifts to Earnings Season	AN
Feb. 23	Piazza Affari Shows Resilience; Enel Drives Mib Higher	AN

Chart Recordati

Duration

Period

REC: Dynamic Chart

Company Profile

Recordati S.p.A. specializes in the research, development, production and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceutical and OTC products (64.4%): for the treatment of viral infections, cardiovascular, dermatological, gynecological diseases, etc.; - medicines for rare diseases (35.6%). Net sales are distributed geographically as follows: Italy (14.3%), Europe (56.1%), America (20.4%), Asia and Oceania (6.7%) and Africa (2.5%).

Employees

4,539

Sector

Pharmaceuticals

Calendar

Mar. 19 - Earnings release - Annual 2025

More about the company